{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:00Z","timestamp":1761896100925},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.006","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T12:12:50Z","timestamp":1439899970000},"page":"S141-S146","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas"],"prefix":"10.1016","volume":"15","author":[{"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.006_bib1","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.006_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.006_bib3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and\u00a0mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.006_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib6","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib7","first-page":"269","article-title":"Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study","author":"Sehn","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib8","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell\u00a0immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.006_bib9","first-page":"8000","article-title":"CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma","author":"Leonard","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib11","first-page":"8521","article-title":"CALGB 50803 (Alliance): a phase II trial of\u00a0lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","author":"Martin","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib12","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib13","first-page":"1820","article-title":"Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 Gather study (GAO4915g)","author":"Zelenetz","year":"2013","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib14","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A\u00a0Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.006_bib18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/10428194.2013.810738","article-title":"Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease","volume":"55","author":"Soumerai","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.02.006_bib19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib21","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.006_bib22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.006_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.02.006_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/asheducation-2013.1.584","article-title":"Treatment strategies for aggressive lymphomas: what works?","author":"Wilson","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2015.02.006_bib27","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.02.006_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the\u00a0therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.006_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.006_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or\u00a0refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib33","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib34","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with\u00a0rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib36","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with\u00a0mantle-cell lymphoma who relapsed or progressed after or were refractory to\u00a0bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib41","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.006_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib43","first-page":"920","article-title":"Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma","author":"Pohlman","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib44","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an Intergroup Study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib47","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib48","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib49","first-page":"673","article-title":"The Aethera trial: results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma","author":"Moskowitz","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib50","first-page":"4400","article-title":"Final results of a phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL)","author":"Palanca-Wessels","year":"2013","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib51","first-page":"S1348","article-title":"Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses","volume":"99","author":"Davids","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.006_bib52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.006_bib53","first-page":"802","article-title":"A\u00a0phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL","author":"Flinn","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib54","first-page":"396","article-title":"The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin lymphoma (NHL)","author":"Kuruvilla","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib55","first-page":"1811","article-title":"Open-label phase 2 study of the bispecific T-cell engager (BiTE) blinatumomab in patients with relapsed\/refractory diffuse large B-cell lymphoma","author":"Goebeler","year":"2013","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.006_bib57","first-page":"289","article-title":"Nivolumab in patients with relapsed or refractory Hodgkin lymphoma-preliminary safety, efficacy and biomarker results of a phase I study","author":"Armand","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib58","first-page":"291","article-title":"Preliminary results of a phase I study of\u00a0nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies","author":"Lesokhin","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib59","first-page":"95","article-title":"Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora a kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL)","author":"Friedberg","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.006_bib60","first-page":"803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","author":"Horwitz","year":"2014","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501500035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501500035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:29:18Z","timestamp":1567074558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501500035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":60,"alternative-id":["S215226501500035X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}